Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy

Annals of Surgical Oncology(2024)10.1245/s10434-024-16382-7Source: DataRank Database

Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy is a research paper published in Annals of Surgical Oncology (2024). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)OA: greenTopics (75)IDs (PubMed)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Min Yi ORCID,Janine M. Simons ORCID,Henry M. Kuerer,Abigail S. Caudle ORCID,Sarah M. DeSnyder

Live enrichment

PubMed:39441324

Clinical Center

Grant: Cancer Center Support Grant CA16672

National Institutes of Health

Grant: 3P30CA016672-41S4

Cancer Center Support (CORE) Grant

NCI NIH HHS

Grant: P30 CA016672

greenLicense: other-oa

repositoryhttps://pure.eur.nl/en/publications/5cb25baf-6160-43a0-9b0a-fe5df453d6e2

publisherhttps://link.springer.com/content/pdf/10.1245/s10434-024-16382-7.pdf

publisherhttps://link.springer.com/article/10.1245/s10434-024-16382-7/fulltext.html

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11710993/

https://doi.org/10.1245/s10434-024-16382-7

Fields of Study

03 medical and health sciences0302 clinical medicineHumansFemaleBreast NeoplasmsNeoadjuvant TherapyMiddle AgedNeoplasm, ResidualErb-b2 Receptor Tyrosine KinasesAgedSentinel Lymph Node BiopsyAxillaSentinel Lymph NodeFollow-Up StudiesAdultCarcinoma, LobularReceptors, EstrogenLymph Node ExcisionReceptors, ProgesteroneAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantLymphatic MetastasisPrognosisCarcinoma, Ductal, BreastLymph NodesRetrospective Studies

MeSH Terms

HumansFemaleBreast NeoplasmsNeoadjuvant TherapyMiddle AgedNeoplasm, ResidualErb-b2 Receptor Tyrosine KinasesAgedSentinel Lymph Node BiopsyAxillaSentinel Lymph NodeFollow-Up StudiesAdultCarcinoma, LobularReceptors, EstrogenLymph Node ExcisionReceptors, ProgesteroneAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantLymphatic MetastasisPrognosisCarcinoma, Ductal, BreastLymph NodesRetrospective Studies

Keywords

AdultNeoplasm, ResidualSentinel Lymph Node BiopsyBreast NeoplasmsMiddle AgedErb-b2 Receptor Tyrosine KinasesArticleNeoadjuvant TherapyCarcinoma, LobularSDG 3 - Good Health and Well-beingReceptors, EstrogenChemotherapy, AdjuvantLymphatic MetastasisAxillaAntineoplastic Combined Chemotherapy ProtocolsHumansLymph Node ExcisionFemaleSentinel Lymph NodeReceptors, ProgesteroneAgedFollow-Up StudiesAxillary managementClinically node-negative breast cancerNeoadjuvant chemotherapy